X
Regulators finally back Merck KGaA oral MS drug
https://pharmaphorum.com/news/regulators-mavenclad/
AbbVie
AbbVie looks beyond Humira as RA pill meets phase 3 targets
June 8, 2017Upadacitinib hopes drug will reduce reliance on Humira.
Sanofi, Regeneron aim to undercut rivals with new RA drug
May 23, 2017New drug will be sold at around 30% discount to rivals.
AbbVie’s 8-week hepatitis C drug granted early access in UK
May 11, 2017AbbVie’s hepatitis C drug granted early access in UK
AbbVie takes aim at Gilead and BMS with 8-week hep C treatment
April 24, 2017Trial backs patient-friendly regime in tough to treat strain.
Doubts over AbbVie PARP inhibitor after double trial failure
April 20, 2017Veliparib fails in two phase 3 trials.
Lilly slumps after FDA rejects RA pill
April 18, 2017Partner Incyte also hit after shock rejection.
UK court overturns AbbVie Humira patents
March 9, 2017Decision paves way for cheaper competitor in autumn 2018.
